Funapide
Funapide is a novel analgesic under development by Xenon [Pharmaceuticals Inc.|Xenon Pharmaceuticals] for the treatment of a variety of chronic pain conditions, including osteoarthritis, neuropathic pain, postherpetic neuralgia, and erythromelalgia, as well as dental pain. It acts as a small-molecule Nav1.7 and Nav1.8 voltage-gated [sodium channel] blocker. Funapide was evaluated in humans in both oral and topical formulations, and as of July 2014, had reached Phases of [clinical research|phase IIb] clinical trials. Development of the drug was discontinued in 2022.